Medical College of Wisconsin
CTSIResearch InformaticsREDCap

CURRICULUM VITAE

Mark J. Moskowitz MD
Adjunct Assistant Professor
Department of Medicine
Division of Medicine Hematology Oncology

OFFICE ADDRESS:
9200 West Wisconsin Avenue
Milwaukee, WI 53226

EDUCATION:
08/1972 - 12/1975 Bachelor of Arts, Southern Illinois University, Carbondale, IN
08/1978 - 06/1982 Doctor of Medicine, Universidad CETEC, Santo Domingo, Dominican Republic
07/1982 - 06/1983 Medicine Internship, West Suburban Hospital, Oak Park, IL
07/1983 - 06/1985 Medicine Residency, Medical College of Wisconsin, Milwaukee, WI
08/1987 - 06/1989 Oncology Fellowship, University of Wisconsin, Carbone Cancer Center, Madison, WI

FACULTY APPOINTMENTS:
07/1985 - 07/1987 Internist, Medical-Surgical Clinic, Milwaukee, WI
07/1987 - 06/1989 A&E Physician, St Francis Hospital, Milwaukee, WI
09/1987 - 06/1989 Urgent Care MD, Dean Medical Center, Madison, WI
07/1989 - 05/2015 Hematologist/Oncologist, Medical Oncology and Malignant Hematology, Florida Cancer Specialists, Ft Myers, FL
10/2017 - Present Clinical Fellow, Christie NHS Trust
02/2025 - Present Adjunct Assistant Professor, Medicine, Medicine, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
01/2016 - 10/2017 Postgraduate Tutor, Macclesfield Dist. General Hospital
07/2016 - 01/2017 Lecturer, School of Oncology, Christie Hospital, Manchester

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Diplomate
1985
None
Diplomate
1989
None
   
Certificates
Issued By Issue DateExpiration
Member
Royal College of Physicians
2023
None
    

Licensure
Number Issue DateExpiration
Registration with license to Practice
7060975
2017
None
    

AWARDS AND HONORS:
1998 - 2015 America’s Top Doctors, Top Doctors in Southwest Florida

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society for Clinical Oncology
American College of Physicians
European Society for Medical Oncology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Prior
Non-Peer Review
Title:
1033IL/0029: 0436-“A Randomized, Double-Blind Trial Comparing ARIMIDEX Alone with Nolvadex with ARIMIDEX and Nolvadex in Combination as Adjuvant Treatment in Postmenopausal Women with Breast Cancer"
Source:
 Zeneca Pharmaceuticals
Role & Effort:
Sub-Investigator
Dates:
1997
  
Title:
1033IL/0030:0121-“A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Anastrozole 1mg daily with Tamoxifen Citrate 20mg daily as First-Line Therapy for Advanced Breast Cancer in Post-Menopausal Women"
Source:
Zeneca Pharmaceuticals
Role & Effort:
Sub-Investigator
Dates:
1997
  
Title:
EFC 4584- “A Multicenter, Open-abel Randomized, Three-Arm Study of 5-Flurouracil (5FU) plus Leucovorin (LV) or Oxaliplatin or a Combination of FU/LV + Oxaliplatin as Second-Line Treatment of Metastatic Colorectal Carcinoma."
Source:
Sanofi-Synthelabo Research
Role & Effort:
Sub-Investigator
Dates:
2001
  
Title:
D0112-“A Multicenter, Randomized Phase III Study of Taxotere and Carboplatin versus Taxotere and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer”
Source:
BioInformatics
Role & Effort:
Sub-Investigator
Dates:
2001
  
Title:
SG0001-015- “Phase II Study of SGN-15 (cR96-Doxorubicin Immunoconjugate) Combined with Taxotere in Patients with Hormone Refractory Prostate Carcinoma"
Source:
Seattle Genetics, Inc.
Role & Effort:
Sub-Investigator
Dates:
2001
  
Title:
 EFC 4585- “A Multicenter, Open-Label Randomized Two-Arm Study of Irinotecan (CPT-11) versus the Combination of Oxaliplatin + Irinotecan as Second-Line Treatment of Metastatic Colorectal Carcinoma"
Source:
Sanofi-Synthelabo
Role & Effort:
Sub-Investigator
Dates:
2002
  
Title:
SG0002-015-“Open-label, Randomized, Phase II Trial of a Drug Immunoconjugate, SGN-15 (cBR96-Doxorubicin) administered Weekly in Combination with Weekly Taxotere in Patients with Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma"
Source:
Seattle Genetics
Role & Effort:
Sub-Investigator
Dates:
2002
  
Title:
CZOL-446 E US16- “A Prospective, Multicenter, Open-Label Clinical Evaluation of the effect of IV Zolendronate 4mg on Pain, Quality of Life and Time in Infusion Chair in Breast Cancer, Multiple Myeloma and Prostate Cancer Patients with Cancer-Related Bone Lesions.”
Source:
Novartis Pharmaceuticals corporation
Role & Effort:
Sub-Investigator
Dates:
2002
  
Title:
ARD5099- “ A Randomized, Prospetive Study Comparing Three Regimens of Eloxatin Plus Fluoropyrimidine and Aastin for Evaluation of Safety and Tolerability in First Line Treatment of Patients with Advanced Colorectal Cancer (Tree 2 Study)”
Source:
Sanofi-Synthelabo
Role & Effort:
Sub-Investigator
Dates:
2003
  
Title:
CC5013-MDS-002: “A multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in RBC Transfusion-Dependent Subjects with Myelodysplastic Syndrome"
Source:
Celgene
Role & Effort:
Sub-Investigator
Dates:
2003
  
Title:
CC5013-MDS-002: “ A multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in RBC Transfusion-Dependent Subjects with Myelodysplastic Syndrome"
Source:
Celgene
Role & Effort:
Sub-Investigator
Dates:
2003
  
Title:
LUN66- “Phase II Trial of Weekly Topotecan in the Second Line Treatment of Small Cell Lung Cancer “
Source:
Sarah Cannon Cancer Center
Role & Effort:
Sub-Investigator
Dates:
2003
  
Title:
D0410- “ A National Web-based Randomized Phase III Study of Erlotinib or Placebo following Concurrent Docetaxel, Carboplatin and Thoracic Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer"
Source:
Dartmouth-Hitchcock Medical Center
Role & Effort:
Sub-investigator
Dates:
2005
  
Title:
GU22- “ A Phase I/II Trial of Bevacizumab, erlotinib and Imitanib in the Treatment of Patients with Advanced Renal Cell Carcinoma"
Source:
Sarah Cannon Cancer Center
Role & Effort:
Sub-investigator
Dates:
2005
  
Title:
GYN-19- “ A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients with Stage III/IV Epithelial Ovarian Cancer
Source:
Cannon Research Institute
Role & Effort:
Sub-investigator
Dates:
2006
  
Title:
GU 32- “Phase II Trial of Bevacizumab and RAD001 (Everolimus) In the Treatment of Patients with Advanced Clear Cell Renal Carcinoma."
Source:
Sarah Cannon Research Institute
Role & Effort:
Sub-investigator
Dates:
2006
  
Title:
EGF 106708- ALLTTO (Adjuvant Lapatanib and/or Trastuzumab Treatment Optimization) Study. “A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatanib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ERB2-Positive Primary Breast Cancer"
Source:
GSK
Role & Effort:
Sub-Investigator
Dates:
2007
  
Title:
LUN 160-“A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer"
Source:
Sarah Cannon Research Institute
Role & Effort:
Sub-Investigator
Dates:
2007
  
Title:
RAD001C2241- “ A Single-Arm, Multicenter, Phase II Study of RAD001 in Patients with Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy with an Anti-EGFR Antibody (bevacizumab), fluoropyrimidine, Oxaliplatin and Irinotecan-Based Regimens
Source:
Novartis
Role & Effort:
Sub-investigator
Dates:
2007
  
Title:
CO5009- “ Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who are Not considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide and Dexamethasone (VTD) versus VELCADE and Dexamethasone versus VELCADE, Melphalan and Prednisone (VPM)”
Source:
Millennium Pharmaceuticals
Role & Effort:
Sub-investigator
Dates:
2007
  
Title:
 H6Q-MC-S028- “ An Open-Label, Randomized, Phase II Study of Rituximab-Cyclophosphamide-Doxorubicin-Vincristine and Prednisone (R-CHOP) Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High Risk Diffuse Large B-Cell Lymphoma"
Source:
Eli Lilly
Role & Effort:
Sub-Investigator
Dates:
2007
  
Title:
CFEM345DUS59- “Open-Label, Single-Arm, Multicenter Study to Evaluate the Rheumatological Tolerability of Letrozole as an Adjuvant Breast Cancer Treatment in Postmenopausal Women who are Intolerant and Discontinue Anastrozole Due to Grade 2-3 Arthralgia-Myalgia"
Source:
Novartis
Role & Effort:
Sub-Investigator
Dates:
2008
  
Title:
Protocol LUN 200: “Randomized, Phase II Double-Blind Trial of Erlotinib and Pazopanib or Erlotinib and Placebo in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. “
Role & Effort:
Sub-investigator
Dates:
2008
  
Title:
Protocol UNK PRI20-“Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients with Carcinoma of Unknown Primary Site”
Source:
Sarah Cannon Research Institute
Role & Effort:
Sub-Investigator
Dates:
2008
  
Title:
COU-AA-301-A “ Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy"
Source:
Cougar Biotechnology
Role & Effort:
Sub-Investigator
Dates:
2008
  
Title:
Protocol D4320C000-33 – “A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of 10mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-Resistant Prostate Cancer”
Source:
Astra-Zeneca
Role & Effort:
Sub-investigator
Dates:
2008
  
Title:
Protocol CR0011-CLN-20-“A Phase I/II Study of CR011-vcMMAE in Patients with Locally Advanced or Metastatic Breast Cancer”
Source:
CuraGen Corporation
Role & Effort:
Sub-Investigator
Dates:
2008
  
Title:
Protocol VEG108844- A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma
Source:
GSK
Role & Effort:
Sub-Investigator
Dates:
2008
  
Title:
NSABP B-44- “A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab"
Role & Effort:
Sub-Investigator
  
Title:
Protocol GU 43- “ Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma"
Role & Effort:
Sub-Investigator
  
Title:
Protocol BRE 138- “Phase II Trial of Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer"
Role & Effort:
Sub-Investigator
  
Title:
Protocol CDX011-03: “ Phase II Randomized, Multicenter Study of CDX-001 in Patients with Advanced GPNMB Breast Cancer"
Role & Effort:
Sub-Investigator
  
Title:
Protocol MEK113487- “ Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 plus Gemcitabine versus Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer"
Role & Effort:
Sub-Investigator
  
Title:
Protocol H3E-US-S130: Randomized, Open-label, Phase III Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell lung Cancer of Non-Squamous Histology"
Role & Effort:
Sub-Investigator
  
Title:
Protocol GI 134- “ Phase II Study of FOLFOXIRI plus Panitumumab Followed by Evaluation for Resection in Patients with Metastatic KRASE Wild-Type Colorectal Cancer with Liver Metastasis Only"
Role & Effort:
Sub-Investigator
  
Title:
Protocol C18083/3064/NLMN- “ Open-Label, Randomized Study of Bendamustine HCl and Rituximab Compared with R-CVP or R-CHOP in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma"
Role & Effort:
Sub-Investigator
  

REFERENCES:
Richard Hubner, MA, BM, BCh MRCP PhD. Consultant in Medical Oncology, Christie NHS Trust, Wilmslow Road, Manchester M20 4BX 0161 446 3000. I have worked with Dr Hubner since 2017. Caroline.leatherbarrow@nhs.net
Mary M. Horowitz, MD, MS, Robert A. Uihlein, Jr. Professor of Hematologic Research; Associate Director, Cancer, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, Wisconsin 53226. 866-680-0505. Marymh@mcw.edu. I have known Dr. Horowitz since 1983. She was my chief resident at MCW.
Professor Gordon Jayson BM, BA, Bch, FRCP, PhD, Professor of Medical Oncology, Chair of Manchester Cancer Systemic Anti-Cancer Therapies Board, Christie NHS Trust, Wilmslow Road, Manchester M20 4BX 0161 446 3000. I have worked with Professor Jayson since 2018 Gordonjayson@nhs.net
Steven B. Newman, MD, Florida Cancer Specialists, 3530 Kraft Road, Suite 300, Naples, FL 34105-5020 239-353-6636, snewman@flcancer.com. I have known Dr Newman for approximately 12 years.
Abbas Chittalia MBBS, MD, MRCP, FRCR. Consultant Clinical Oncologist, Christie NHS Trust, Wilmslow Road, Manchester M20 4BX 0161 446 3000. I have worked with Dr Chittalia since 2017.Abbas.Chittalia@nhs.net
Professor Was Mansoor, MD, PhD., FRCP, Professor of Medical oncology, Systemic Cancer Research Chair, Christie NHS Trust, Wilmslow Road, Manchester M20 4BX. 0161 446 3000. I have worked with Dr Mansour since 2017. Was.mansoor@nhs.net
Konstantinos Kamposioras, MD, FRCP, PhD, Consultant in Medical Oncology, Christie NHS Trust, Wilmslow Road, Manchester M20 4BX 0161 446 3000 I have worked with Dr Kamposioras since 2019. Konstantinos.Kamposioras@nhs.net


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Spiers, A, Moskowitz, M, Moscinski, L, Papenhausen P. “Myelodysplastic Syndrome: Refractory Anemia with Excess Blasts Transforming to Acute Myeloid Leukemia and Reconverting to RAEB with Single-Agent Erythropoietin” Blood. .
2. Harvey, W, Moskowitz, M. “Ciprofloxacin/Vancomycin as Initial Empiric Therapy in Febrile Neutropenic Leukemia/Lymphoma Patients with Indwelling Venous Access Devices. Preliminary Results of an Effective Regimen with Reduced Hospital Stay” Proc ASCO: Vol 13, p471. .